VivekSharadKavadiMD

Radiation Oncology • Sugar Land, TX

Physician

Join to view full profile

Dr. Kavadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kavadi's full profile

Already have an account?

Office
1350 First Colony Blvd
Sugar Land, TX 77479
Phone+1 281-277-5200

Fax+1 281-276-3492
Is this information wrong?

Education & Training

University of Texas M D Anderson Cancer CenterResidency, Radiation Oncology, 1989 - 1993
Baylor College of MedicineInternship, Transitional Year, 1988 - 1989
Harvard Medical SchoolClass of 1988

Certifications & Licensure

CA State Medical License 1993 - 2025
TX State Medical License 1989 - 2024
MD State Medical License 1994 - 1996
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013

Clinical Trials

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 01
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y Chang, Bo Lu, Adam P Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Nara...> ;Cancer Research Communications. 2023 Oct 11
9 citations
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutio...
Daniel J Krauss, Theodore Karrison, Alvaro A Martinez, Gerard Morton, Di Yan, Deborah Watkins Bruner, Benjamin Movsas, Mohamed Elshaikh, Deborah Citrin, Bruce Hershatt...> ;Journal of Clinical Oncology. 2023 Jun 10
3 citations
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/R...
Benjamin Movsas, Joseph P Rodgers, Mohamed A Elshaikh, Alvaro A Martinez, Gerard C Morton, Daniel J Krauss, Di Yan, Deborah E Citrin, Bruce W Hershatter, Jeff M Michal...> ;Journal of Clinical Oncology. 2023 Jun 10
2 citations
A Medicare Claims Analysis of Racial and Ethnic Disparities in the Access to Radiation Therapy Services.
Constantine A Mantz, Nikhil G Thaker, Curtiland Deville Jr, Anne Hubbard, Praveen Pendyala, Najeeb Mohideen, Vivek Kavadi, Karen M Winkfield> ;Journal of Racial and Ethnic Health Disparities. 2023 Apr 1
29 citations
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.
Jian-Yue Jin, Chen Hu, Ying Xiao, Hong Zhang, Rebecca Paulus, Susannah G Ellsworth, Steven E Schild, Jeffrey A Bogart, Michael Chris Dobelbower, Vivek S Kavadi, Samir ...> ;Cancers. 2021 Dec 8
1 citations
Radiation Oncology's Place in Payment Reform: ASTRO Advocates for a Place at the Table
Anne Hubbard, Constantine Mantz, Najeeb Mohideen, William Hartsell, Nikhil G. Thaker, Peter F. Orio, Catheryn M. Yashar, Vivek Kavadi, Brian D. Kavanagh, Dave Adler> ;JCO Oncology Practice. 2021 Sep 15
1 citations
Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement.
Nikhil G. Thaker, Rehman Meghani, Cassandra Wilson, Jody Garey, Philip Nelson, Gautam H. Thaker, Chirag Shah, Peter F. Orio, Catheryn M. Yashar, Vivek Kavadi> ;Brachytherapy. 2021 Jul 5
17 citations
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Thomas B. Julian, David S. Parda, Samantha A. Seaward, Dennis L...> ;Journal of Clinical Oncology. 2021 Mar 19
2 citations
Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons Learned.
X. Allen Li, Jennifer Moughan, Julia White, Gary M. Freedman, Douglas W. Arthur, James M. Galvin, Ying Xiao, Susan McNulty, Janice A. Lyons, V.S. Kavadi, Marc T. Field...> ;Practical Radiation Oncology. 2020 Jul 1
1 citations
The ASTRO Perspective on "Impact of Patient Stage and Disease Characteristics on the Proposed Radiation Oncology Alternative Payment Model (RO-APM) at a Large Academic...
Najeeb Mohideen, Vivek S. Kavadi, Constantine Mantz, Anne Hubbard> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Apr 1
233 citations
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Kenneth M. Forster, Anthony M. Magliocco,...> ;Journal of Clinical Oncology. 2020 Mar 1
37 citations
Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617.
Maria Thor, Joseph O. Deasy, Chen Hu, Elizabeth Gore, Voichita Bar-Ad, Clifford G. Robinson, Matthew Wheatley, Jung Hun Oh, Jeffrey A. Bogart, Yolanda I. Garces, V.S. ...> ;Clinical Cancer Research. 2020 Jan 1
439 citations
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomize...
Stephen G. Chun, Chen Hu, Hak Choy, R.U. Komaki, Robert Timmerman, Steven E. Schild, Jeffrey A. Bogart, Michael C. Dobelbower, Walter Bosch, James M. Galvin, V.S. Kava...> ;Journal of Clinical Oncology. 2017 Jan 1
73 citations
Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.
Bree R. Eaton, Stephanie L. Pugh, Jeffrey D. Bradley, Greg Masters, V.S. Kavadi, Samir Narayan, Lucien A. Nedzi, Cliff G. Robinson, Raymond B. Wynn, Christopher Koprow...> ;Journal of the National Cancer Institute. 2016 Sep 1
119 citations
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group...
Benjamin Movsas, Chen Hu, Jeff A. Sloan, Jeffrey D. Bradley, Ritsuko Komaki, Gregory A. Masters, V.S. Kavadi, Samir Narayan, Jeff M. Michalski, Douglas W. Johnson, Chr...> ;JAMA Oncology. 2016 Mar 1
1284 citations
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage I...
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Chen Hu, Kenneth M. Forster, Antho...> ;The Lancet. Oncology. 2015 Feb 1
17 citations
Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.
Chul S. Ha, Vivek S. Kavadi, Meletios A. Dimopoulos, Frederick B. Hagemeister, Barbara M. Osborne, Lillian M. Fuller, Terry L. Smith, Mark A. Hess, Peter McLaughlin, F...> ;International Journal of Radiation Oncology, Biology, Physics. 1999 Jan 15
104 citations
Lymphoma of the nasal cavity and paranasal sinuses: Improved outcome and altered prognostic factors with combined modality therapy
Mark D Logsdon, Chul S. Ha, Vivek S. Kavadi, Fernando Cabanillas, Mark A. Hess, James D. Cox> ;Cancer. 1997 Aug 1
137 citations
Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
Gunar K. Zagars, Alan Pollack, Vivek S. Kavadi, Andrew C. von Eschenbach> ;International Journal of Radiation Oncology, Biology, Physics. 1995 May 15
21 citations
The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer—T, N, or M?
Gunar K. Zagars, Vivek S. Kavadi, Alan Pollack, Andrew C. von Eschenbach, M.Elizabeth Sands> ;International Journal of Radiation Oncology, Biology, Physics. 1995 Apr 30
71 citations
Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications
Vivek S. Kavadi, Gunar K. Zagars, Alan Pollack> ;International Journal of Radiation Oncology, Biology, Physics. 1994 Sep 30
108 citations
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer
Alan Pollack, Gunar K. Zagars, Vivek S. Kavadi> ;Cancer. 1994 Jul 15
12 citations
FIGO stage IIIA carcinoma of the uterine cervix
Vivek S. Kavadi, Patricia J. Eifel> ;International Journal of Radiation Oncology, Biology, Physics. 1992 Jan 1
Reduce in variation and improve efficiency of target volume delineation by a computer-assisted system using a deformable image registration approach.
Chao, K. S., Bhide, S., Chen, H., Asper, J., Bush, S., Franklin, G., Kavadi, V., Liengswangwong, V., Gordon, W., Raben, A., Strasser, J., Koprowski, C., Frank, S., Chr...> ;Int J Radiat Oncol Biol Phys. 2007 Aug 1
Join now to see all

Press Mentions

Launch of Covid-19 Vaccine in India Has ‘Rescued the World’ from Pandemic, Says Leading American Scientist India NewsMarch 7th, 2021
Leaders in Radiation Oncology Awarded ASTRO Fellow DesignationAugust 8th, 2019
Vivek S. Kavadi, M.D., FASTRO, to Be Honored by the American Society for Radiation OncologyAugust 7th, 2019
Join now to see all